Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 1
2019 3
2020 3
2021 2
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
TIGIT blockade repolarizes AML-associated TIGIT+ M2 macrophages to an M1 phenotype and increases CD47-mediated phagocytosis.
Brauneck F, Fischer B, Witt M, Muschhammer J, Oelrich J, da Costa Avelar PH, Tsoka S, Bullinger L, Seubert E, Smit DJ, Bokemeyer C, Ackermann C, Wellbrock J, Haag F, Fiedler W. Brauneck F, et al. Among authors: muschhammer j. J Immunother Cancer. 2022 Dec;10(12):e004794. doi: 10.1136/jitc-2022-004794. J Immunother Cancer. 2022. PMID: 36549780 Free PMC article.
Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells in vitro.
Brauneck F, Oliveira-Ferrer L, Muschhammer J, Sturmheit T, Ackermann C, Haag F, Schulze Zur Wiesch J, Ding Y, Qi M, Hell L, Schmalfeldt B, Bokemeyer C, Fiedler W, Wellbrock J. Brauneck F, et al. Among authors: muschhammer j. Front Immunol. 2023 Oct 2;14:1250258. doi: 10.3389/fimmu.2023.1250258. eCollection 2023. Front Immunol. 2023. PMID: 37876933 Free PMC article.
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer.
Stamm H, Oliveira-Ferrer L, Grossjohann EM, Muschhammer J, Thaden V, Brauneck F, Kischel R, Müller V, Bokemeyer C, Fiedler W, Wellbrock J. Stamm H, et al. Among authors: muschhammer j. Oncoimmunology. 2019 Oct 12;8(12):e1674605. doi: 10.1080/2162402X.2019.1674605. eCollection 2019. Oncoimmunology. 2019. PMID: 31741778 Free PMC article.
Suppression of Neutrophil-Mediated Tissue Damage-A Novel Skill of Mesenchymal Stem Cells.
Jiang D, Muschhammer J, Qi Y, Kügler A, de Vries JC, Saffarzadeh M, Sindrilaru A, Beken SV, Wlaschek M, Kluth MA, Ganss C, Frank NY, Frank MH, Preissner KT, Scharffetter-Kochanek K. Jiang D, et al. Among authors: muschhammer j. Stem Cells. 2016 Sep;34(9):2393-406. doi: 10.1002/stem.2417. Epub 2016 Jun 27. Stem Cells. 2016. PMID: 27299700 Free PMC article.
Newly Defined ATP-Binding Cassette Subfamily B Member 5 Positive Dermal Mesenchymal Stem Cells Promote Healing of Chronic Iron-Overload Wounds via Secretion of Interleukin-1 Receptor Antagonist.
Vander Beken S, de Vries JC, Meier-Schiesser B, Meyer P, Jiang D, Sindrilaru A, Ferreira FF, Hainzl A, Schatz S, Muschhammer J, Scheurmann NJ, Kampilafkos P, Seitz AM, Dürselen L, Ignatius A, Kluth MA, Ganss C, Wlaschek M, Singh K, Maity P, Frank NY, Frank MH, Scharffetter-Kochanek K. Vander Beken S, et al. Among authors: muschhammer j. Stem Cells. 2019 Aug;37(8):1057-1074. doi: 10.1002/stem.3022. Epub 2019 May 13. Stem Cells. 2019. PMID: 31002437 Free PMC article.
13 results